128 related articles for article (PubMed ID: 34127273)
1. Unexpected Findings During Double-blind Discontinuation of Acetylcholinesterase Inhibitor Medications.
Moo LR; Martinez E; Padala K; Dunay MA; Scali RR; Chen S; Thielke SM
Clin Ther; 2021 Jun; 43(6):942-952. PubMed ID: 34127273
[TBL] [Abstract][Full Text] [Related]
2. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated With Deprescribing Acetylcholinesterase Inhibitors in Older Nursing Home Residents With Severe Dementia.
Niznik JD; Zhao X; He M; Aspinall SL; Hanlon JT; Nace D; Thorpe JM; Thorpe CT
J Am Geriatr Soc; 2019 Sep; 67(9):1871-1879. PubMed ID: 31162642
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease.
Mantri S; Fullard M; Gray SL; Weintraub D; Hubbard RA; Hennessy S; Willis AW
JAMA Neurol; 2019 Jan; 76(1):41-49. PubMed ID: 30285047
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.
Duffy L; Clarke CS; Lewis G; Marston L; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Mangin D; Moore M; Nazareth I; Wiles N; Bacon F; Bird M; Brabyn S; Burns A; Donkor Y; Hunt A; Pervin J; Lewis G
Health Technol Assess; 2021 Nov; 25(69):1-62. PubMed ID: 34842135
[TBL] [Abstract][Full Text] [Related]
6. Cholinesterase inhibitors for Parkinson's disease dementia.
Maidment I; Fox C; Boustani M
Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
[TBL] [Abstract][Full Text] [Related]
7. Adverse outcomes of abrupt switch and discontinuation of acetylcholinesterase inhibitors in dementia with Lewy bodies: Case report and literature review.
Greiman TL; Dear BN; Wilkening GL
Ment Health Clin; 2019 Sep; 9(5):309-314. PubMed ID: 31534872
[TBL] [Abstract][Full Text] [Related]
8. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Rolinski M; Fox C; Maidment I; McShane R
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
[TBL] [Abstract][Full Text] [Related]
10. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
11. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.
Daiello LA; Ott BR; Lapane KL; Reinert SE; Machan JT; Dore DD
Am J Geriatr Pharmacother; 2009 Apr; 7(2):74-83. PubMed ID: 19447360
[TBL] [Abstract][Full Text] [Related]
12. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
Dubois B; Tolosa E; Katzenschlager R; Emre M; Lees AJ; Schumann G; Pourcher E; Gray J; Thomas G; Swartz J; Hsu T; Moline ML
Mov Disord; 2012 Sep; 27(10):1230-8. PubMed ID: 22915447
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and patterns of the concurrent use of anticholinergics for the motor symptoms of Parkinson's disease and acetylcholinesterase inhibitors in Parkinson's disease patients with dementia: a cross-sectional study using Korea National Health Insurance claims data.
Baik D; Yu YM; Jung SY; Kang HY
BMC Geriatr; 2022 Jul; 22(1):609. PubMed ID: 35864474
[TBL] [Abstract][Full Text] [Related]
14. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.
Ravina B; Putt M; Siderowf A; Farrar JT; Gillespie M; Crawley A; Fernandez HH; Trieschmann MM; Reichwein S; Simuni T
J Neurol Neurosurg Psychiatry; 2005 Jul; 76(7):934-9. PubMed ID: 15965198
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
Emre M; Poewe W; De Deyn PP; Barone P; Kulisevsky J; Pourcher E; van Laar T; Storch A; Micheli F; Burn D; Durif F; Pahwa R; Callegari F; Tenenbaum N; Strohmaier C
Clin Neuropharmacol; 2014; 37(1):9-16. PubMed ID: 24434526
[TBL] [Abstract][Full Text] [Related]
16. Rivastigmine for dementia associated with Parkinson's disease.
Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
[TBL] [Abstract][Full Text] [Related]
17. [Acetylcholinesterase inhibitors for dementia--an update].
Anghelescu I; Heuser I
MMW Fortschr Med; 2007 May; 149 Suppl 2():76-8. PubMed ID: 17724973
[TBL] [Abstract][Full Text] [Related]
18. Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia.
Masurkar PP; Chatterjee S; Sherer JT; Aparasu RR
Drugs Aging; 2021 Jul; 38(7):593-602. PubMed ID: 34027602
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of acetylcholinesterase inhibitor treatment in the nursing home.
Mansour D; Wong R; Kuskowski M; Dysken M
Am J Geriatr Pharmacother; 2011 Oct; 9(5):345-50. PubMed ID: 21925960
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
